Advertisement
Journal Home
Search for

Volume 19, Issue 3, Pages 133-137 (May 2005)


View previous. 9 of 11 View next.

Prevalence of antiphospholipid antibodies is not different in Chilean diabetic patients and normal individuals

Iván G. Palomoa, Verónica E. Mujicab, Marcelo L. Alarcóna, Jaime G. Pereirac, Marcela R. VásquezaCorresponding Author Informationemail address

Received 16 July 2003; received in revised form 3 September 2004; accepted 21 September 2004.

Abstract 

Diabetes mellitus (DM) is complicated by vascular and neurological events. Antiphospholipid (aPL) antibodies have already been associated with many clinical conditions, including venous and arterial thrombosis, as well as recurrent fetal loss. However, a significant association between aPL antibodies and DM has not been widely reported yet. In the present study, we investigated the prevalence of aPL antibodies in diabetic patients. This study included 100 Chilean diabetic patients (67 of them with some complications and 33 without complications; 28 with Type 1 and 72 with Type 2 DM) and 100 healthy blood donor controls. Each sample was analyzed for IgG, IgM and IgA anticardiolipin (aCL), anti-β2 glycoprotein I (anti-β2GPI), antiprothrombin (aPT) antibodies, and lupus anticoagulant (LA). Fourteen out of 100 (14%) diabetic patients presented some type of aPL antibodies. Four patients were positive for aCL antibodies, two for anti-β2GPI antibodies, and nine for aPT antibodies. All patients were LA negative. The incidence of different isotypes was similar in each of the aPL antibodies studied, and their activities were low. No significant correlation was observed between aPL antibodies and vascular complications.

a Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile

b Servicio de Medicina (Medical Service), Hospital Regional de Talca, Talca, Chile

c Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Corresponding Author InformationCorresponding author. Tel.: +56 71 200494; fax: +56 71 200488.

PII: S1056-8727(04)00100-X

doi:10.1016/j.jdiacomp.2004.09.004


View previous. 9 of 11 View next.

Advertisement